- 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: N/A
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
2023 (10) | -8.62 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2022 (9) | -5.87 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
---|---|---|---|---|---|---|---|---|---|
24Q3 (20) | -1.76 | 1.12 | 33.33 | -1.82 | 6.67 | 13.74 | -5.09 | -52.4 | 24.37 |
24Q2 (19) | -1.78 | -14.1 | 35.27 | -1.95 | -26.62 | 11.76 | -3.34 | -114.1 | 18.34 |
24Q1 (18) | -1.56 | 26.76 | -16.42 | -1.54 | 14.92 | -46.67 | -1.56 | 81.9 | -16.42 |
23Q4 (17) | -2.13 | 19.32 | -37.42 | -1.81 | 14.22 | -66.06 | -8.62 | -28.08 | -46.85 |
23Q3 (16) | -2.64 | 4.0 | -72.55 | -2.11 | 4.52 | -77.31 | -6.73 | -64.55 | -74.81 |
23Q2 (15) | -2.75 | -105.22 | -17.52 | -2.21 | -110.48 | -21.43 | -4.09 | -205.22 | -74.79 |
23Q1 (14) | -1.34 | 13.55 | 0 | -1.05 | 3.67 | 0 | -1.34 | 77.17 | 0 |
22Q4 (13) | -1.55 | -1.31 | 0 | -1.09 | 8.4 | 0 | -5.87 | -52.47 | -3.71 |
22Q3 (12) | -1.53 | 34.62 | 0 | -1.19 | 34.62 | 0 | -3.85 | -64.53 | 0 |
22Q2 (11) | -2.34 | 0 | 0 | -1.82 | 0 | 0 | -2.34 | 0 | 0 |
年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
---|---|---|---|---|---|---|---|---|---|---|
2024/11 | 0.02 | 11.68 | 215.29 | 0.18 | 6.87 | 0.05 | N/A | 較去年同期增加係因合作醫院、細胞治療類型及案件數量增加所致 | ||
2024/10 | 0.01 | -19.46 | -15.68 | 0.16 | 0.52 | 0.05 | N/A | - | ||
2024/9 | 0.02 | 15.97 | 45.4 | 0.15 | 2.36 | 0.05 | 1.2 | - | ||
2024/8 | 0.02 | -13.47 | -9.78 | 0.13 | -1.46 | 0.05 | 1.3 | - | ||
2024/7 | 0.02 | 25.88 | 0.57 | 0.12 | -0.28 | 0.05 | 1.31 | - | ||
2024/6 | 0.01 | -5.48 | -42.13 | 0.1 | -0.43 | 0.05 | 1.0 | - | ||
2024/5 | 0.01 | -32.95 | 4.66 | 0.09 | 12.5 | 0.05 | 0.92 | - | ||
2024/4 | 0.02 | 19.95 | 79.24 | 0.07 | 14.25 | 0.06 | 0.89 | 本期拓展新的合作醫療院所及目前合作的醫療院所增加「細胞治療」營業收入,故較去年同期增加超過50% | ||
2024/3 | 0.02 | 10.0 | -10.37 | 0.05 | -1.32 | 0.0 | N/A | - | ||
2024/2 | 0.02 | 7.35 | 19.06 | 0.03 | 4.7 | 0.0 | N/A | - | ||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A |